Features of the patients with SS-associated NHLs (SSL)
| Features | Patients with SSL (n=35) |
| Type | |
| MALT, n (%) | 28 (80) |
| NMZL, n (%) | 2 (5.7) |
| LP, n (%) | 1 (2.8) |
| DLCBL, n (%) | 2 (5.7) |
| SLL, n (%) | 1 (2.8) |
| BALT, n (%) | 1 (2.8) |
| Involved organs | |
| Nodal, n (%) | 8 (22.9) |
| Extranodal | |
| MSG, n (%) | 26 (74.3) |
| Parotid gland (PG), n (%) | 7 (20.0) |
| Both MSG and PG, n (%) | 4 (11.4) |
| Stomach, n (%) | 3 (8.5) |
| Lung, n (%) | 2 (5.7) |
| Nodal and extranodal, n (%) | 4 (11.4) |
| Bone marrow infiltration, n (%) | 10 (28.6) |
| Splenomegaly, n (%) | 4 (11.4) |
| Ann Arbor staging | |
| I, n (%) | 17 (48.6) |
| II, n (%) | 0 (0.0) |
| III, n (%) | 3 (8.5) |
| IV, n (%) | 15 (42.9) |
| IPI score | |
| 0, n (%) | 7 (20.0) |
| 1, n (%) | 5 (14.3) |
| 2, n (%) | 15 (42.9) |
| 3, n (%) | 7 (20.0) |
| 4, n (%) | 1 (2.8) |
| ECOG | |
| 0, n (%) | 30 (85.7) |
| 1, n (%) | 5 (14.3) |
| EFS (months), median (range) | 61.7 (14–206) |
| OS (months), median (range) | 68.4 (14–206) |
BALT, B cell bronchial associated lymphoid tissue; DLCBL, diffuse large B cell lymphoma; ECOG, Eastern Cooperative Oncology Group performance status; EFS, event-free survival; IPI, International Prognostic Index; LP, lymphoplasmacytic; MALT, mucosa-associated lymphoid tissuel; MSG, minor salivary gland; NHL, non-Hodgkin’s lymphoma; NMZL, nodal marginal zone lymphoma; OS, overall survival; SLL, small lymphocytic lymphoma; SS, Sjögren’s syndrome.